Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer

ACTA ONCOLOGICA

TAYLOR & FRANCIS LTD

1. Bayer
2. ESMO